Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High at $45.12

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report)'s stock price hit a new 52-week high on Monday . The company traded as high as $45.12 and last traded at $45.10, with a volume of 110433 shares. The stock had previously closed at $42.37.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Scotiabank increased their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a "sector outperform" rating in a research note on Monday, May 6th. The Goldman Sachs Group raised Twist Bioscience from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Barclays increased their price target on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an "overweight" rating in a report on Friday, May 3rd. Robert W. Baird upped their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, May 3rd. Finally, Evercore ISI lifted their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience has an average rating of "Buy" and a consensus target price of $42.50.

Twist Bioscience Trading Up 11.9 %

The stock has a fifty day moving average price of $34.33 and a 200-day moving average price of $32.08. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -14.12 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. During the same period in the previous year, the business earned ($1.06) earnings per share. The company's revenue for the quarter was up 25.1% compared to the same quarter last year. On average, equities analysts expect that Twist Bioscience Co. will post -3.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the sale, the chief executive officer now owns 515,281 shares in the company, valued at $17,272,219.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the sale, the chief executive officer now directly owns 515,281 shares of the company's stock, valued at $17,272,219.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,487 shares of the business's stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now owns 516,409 shares of the company's stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,415 shares of company stock worth $614,504. 3.92% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the fourth quarter valued at about $30,000. Federated Hermes Inc. acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. boosted its stake in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company's stock worth $30,000 after acquiring an additional 721 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company's stock valued at $70,000 after purchasing an additional 1,179 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Twist Bioscience in the first quarter valued at approximately $124,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.